Related Experiment Video
Updated: Oct 15, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Factors affecting statin uptake among people living with HIV: primary care provider perspectives
Allison J Ober1, Sae Takada2,3, Deborah Zajdman2
1RAND Corporation, Santa Monica, CA, USA. ober@rand.org.
Insights
Statin under-prescription for people with HIV (PLWH) is common. Providers need clearer guidance on cardiovascular disease (CVD) risk assessment and statin use in PLWH to improve care.
Area of Science:
- Implementation Science
- Public Health
- Cardiology
Background:
- Cardiovascular disease (CVD) poses a significant health risk for people living with HIV (PLWH).
- Statin therapy is effective and safe for PLWH but is under-prescribed in clinical settings.
- This study investigates barriers and facilitators to statin prescribing for PLWH.
Purpose of the Study:
- To examine clinic leadership and provider perceptions of factors influencing statin prescribing for PLWH.
- To identify implementation challenges and opportunities for improving statin use in HIV care.
Main Methods:
- Semi-structured telephone interviews were conducted with 39 clinic leaders and providers across eight Los Angeles community health clinics.
- The Consolidated Framework for Implementation Research (CFIR) guided interview questions and qualitative content analysis.
- Current cardiovascular disease risk assessment and statin prescribing practices were also assessed.
Main Results:
- Cardiovascular disease risk assessment is standard but varies in practice, with provider uncertainty regarding HIV-specific risk adjustments.
- Clinic and patient priorities, along with time constraints, hinder comprehensive CVD risk assessment in PLWH.
- Providers expressed a need for more data and standardized guidance on statin therapy for PLWH.
Conclusions:
- While CVD risk assessment and statin prescribing align with primary care, clinics must prioritize these areas to enhance uptake.
- Clearer guidelines are needed on HIV's impact on CVD risk, risk threshold adjustments, optimal statin selection for those on antiretroviral therapy, and shared decision-making.
Background:
Cardiovascular disease (CVD) is a major cause of morbidity and mortality among people living with HIV (PLWH), but statin therapy, safe and effective for PLWH, is under-prescribed. This study examined clinic leadership and provider perceptions of factors associated with statin prescribing for PLWH receiving care in eight community health clinics across Los Angeles, California.
Methods:
We conducted semi-structured telephone interviews with clinic leadership and providers across community health clinics participating in a larger study (INSPIRE) aimed at improving statin prescribing through education and feedback. Clinics included federally qualified health centers (N = 5), community clinics (N = 1) and county-run ambulatory care clinics (N = 2). Leadership and providers enrolled in INSPIRE (N = 39) were invited to participate in an interview. We used the Consolidated Framework for Implementation Research (CFIR) to structure our interview guide and analysis. We used standard qualitative content analysis methods to identify themes within CFIR categories; we also assessed current CVD risk assessment and statin-prescribing practices.
Results:
Participants were clinic leaders (n = 6), primary care physicians with and without an HIV specialization (N = 6, N = 6, respectively), infectious diseases specialists (N = 12), nurse practitioners, physician assistants and registered nurses (N = 7). Ninety-five percent of providers from INSPIRE participated in an interview. We found that CVD risk assessment for PLWH is standard practice but that there is variation in risk assessment practices and that providers are unsure whether or how to adjust the risk threshold to account for HIV. Time, clinic and patient priorities impede ability to conduct CVD risk assessment with PLWH.
Conclusions:
Providers desire more data and standard practice guidance on prescribing statins for PLWH, including estimates of the effect of HIV on CVD, how to adjust the CVD risk threshold to account for HIV, which statins are best for people on antiretroviral therapy and on shared decision-making around prescribing statins to PLWH. While CVD risk assessment and statin prescribing fits within the mission and workflow of primary care, clinics may need to emphasize CVD risk assessment and statins as priorities in order to improve uptake.
Related Concept Videos
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Factors Affecting Drug Response: Overview
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Factors Affecting Drug Distribution: Miscellaneous Factors
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...
Factors Affecting Drug Distribution: Physiological Barriers
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...

